3-Bromo-5-chloropicolinonitrile | CAS:760207-83-8

We serve 3-Bromo-5-chloropicolinonitrile CAS:760207-83-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3-Bromo-5-chloropicolinonitrile

Chemical Name:3-Bromo-5-chloropicolinonitrile
CAS.NO:760207-83-8
Synonyms:3-Bromo-5-chloropicolinonitrile
3-bromo-5-chloropyridine-2-carbonitrile
3-Bromo-5-chloro-2-pyridinecarbonitrile
3-Bromo-2-cyano-5-chloropyridine
 
Physical and Chemical Properties:
Density 1.9±0.1 g/cm3
Boiling Point 297.5±40.0 °C at 760 mmHg
Molecular Formula C6H2BrClN2
Molecular Weight 217.451
Flash Point 133.7±27.3 °C
 
Specification:
Appearance:Pale yellow solid
Assay:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 3-Bromo-5-chloropicolinonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Bromo-2-cyano-5-chloropyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Bromo-5-chloropicolinonitrile Use and application,3-bromo-5-chloropyridine-2-carbonitrile technical grade,usp/ep/jp grade.


Related News: Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector.(E)-6-Iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole manufacturer Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.3H-1,3,4-thiadiazole-2-thione supplier Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.(S)-1,2,3,4-Tetrahydro-1-Naphthoic Acid vendor Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.The latest outbreak comes as China grapples with an African swine fever epidemic that has infected tens of thousands of pigs. It could stoke more worries among its people about the country’s food supply.